Literature DB >> 23264273

Successful treatment of massive intractable pericardial effusion in a patient with systemic lupus erythematosus with tocilizumab.

Yasuyuki Kamata1, Seiji Minota.   

Abstract

A 51-year-old Japanese woman developed systemic lupus erythematosus (SLE) in 1995. In August 2005, she had massive pericardial effusion due to lupus pericarditis, which was compromising her circulation. Methylprednisolone pulse, intravenous cyclophosphamide pulse and pericardiocentesis were all ineffective. The pericardium was cut surgically to create a passage to drain the liquid into the pleural cavity. The procedure was temporarily effective; however, massive liquid accumulated in the pleural cavity within 1 year. Oral tacrolimus and topical betamethasone injection were ineffective. Since the interleukin-6 (IL-6) level in the effusion was markedly increased (1160 pg/ml), tocilizumab was administered intravenously at a dose of 8 mg/kg every 4 weeks. The effect was astonishing and only a residual amount of pericardial effusion remained. Prednisolone was tapered successfully from 15 to 5 mg daily. Tocilizumab is a treatment of choice when we confront an intractable serositis with massive effusion in SLE, if the IL-6 level is high.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23264273      PMCID: PMC4544961          DOI: 10.1136/bcr-2012-007834

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  16 in total

1.  Lymphocyte populations and cytokine concentrations in pericardial fluid from a systemic lupus erythematosus patient with cardiac tamponade.

Authors:  L M Vilá; J R Rivera del Río; Z Ríos; E Rivera
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Authors:  Gabor G Illei; Yuko Shirota; Cheryl H Yarboro; Jimmy Daruwalla; Edward Tackey; Kazuki Takada; Thomas Fleisher; James E Balow; Peter E Lipsky
Journal:  Arthritis Rheum       Date:  2010-02

3.  A case of rheumatoid pericarditis associated with a high IL-6 titer in the pericardial fluid and tocilizumab treatment.

Authors:  Yoshio Ozaki; Akihiro Tanaka; Keiko Shimamoto; Hideki Amuro; Katsuyuki Kawakami; Yonsu Son; Tomoki Ito; Takahiko Wada; Shosaku Nomura
Journal:  Mod Rheumatol       Date:  2010-11-23       Impact factor: 3.023

4.  Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.

Authors:  Masahiko Mihara; Keiko Kasutani; Makoto Okazaki; Akito Nakamura; Shigeto Kawai; Masamichi Sugimoto; Yoshihiro Matsumoto; Yoshiyuki Ohsugi
Journal:  Int Immunopharmacol       Date:  2005-11       Impact factor: 4.932

5.  Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

Authors:  Shumpei Yokota; Tomoyuki Imagawa; Masaaki Mori; Takako Miyamae; Yukoh Aihara; Shuji Takei; Naomi Iwata; Hiroaki Umebayashi; Takuji Murata; Mari Miyoshi; Minako Tomiita; Norihiro Nishimoto; Tadamitsu Kishimoto
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

6.  Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.

Authors:  Norihiro Nishimoto; Kimio Terao; Toru Mima; Hideko Nakahara; Nobuhiro Takagi; Takahiro Kakehi
Journal:  Blood       Date:  2008-09-10       Impact factor: 22.113

7.  Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab.

Authors:  Norihiro Nishimoto; Jun Hashimoto; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Shinichi Kawai; Tsutomu Takeuchi; Norikazu Murata; Désirée van der Heijde; Tadamitsu Kishimoto
Journal:  Ann Rheum Dis       Date:  2007-05-07       Impact factor: 19.103

8.  Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth.

Authors:  K Sato; M Tsuchiya; J Saldanha; Y Koishihara; Y Ohsugi; T Kishimoto; M M Bendig
Journal:  Cancer Res       Date:  1993-02-15       Impact factor: 12.701

9.  Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.

Authors:  Atsushi Ogata; Toshio Tanaka
Journal:  Int J Rheumatol       Date:  2012-01-18

10.  Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.

Authors:  Norihiro Nishimoto; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Shinichi Kawai; Tsutomu Takeuchi; Junichi Azuma; Tadamitsu Kishimoto
Journal:  Mod Rheumatol       Date:  2008-11-01       Impact factor: 3.023

View more
  8 in total

Review 1.  Future prospects in biologic therapy for systemic lupus erythematosus.

Authors:  William Stohl
Journal:  Nat Rev Rheumatol       Date:  2013-09-10       Impact factor: 20.543

Review 2.  Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implications.

Authors:  Natasha Jordan; David D'Cruz
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-12       Impact factor: 5.346

3.  Successful treatment of recurrent pleural and pericardial effusions with tocilizumab in a patient with systemic lupus erythematous.

Authors:  Vanessa Ocampo; Derek Haaland; K Legault; Shika Mittoo; Emily Aitken
Journal:  BMJ Case Rep       Date:  2016-08-08

Review 4.  Inhibition of the interleukin-6 signaling pathway: a strategy to induce immune tolerance.

Authors:  Cheng Zhang; Xi Zhang; Xing-Hua Chen
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

Review 5.  Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside.

Authors:  D Squatrito; G Emmi; E Silvestri; L Ciucciarelli; M M D'Elios; D Prisco; L Emmi
Journal:  Auto Immun Highlights       Date:  2014-08-14

6.  Tocilizumab for massive refractory pleural effusion in an adolescent with systemic lupus erythematosus.

Authors:  Arianna De Matteis; Emanuela Sacco; Camilla Celani; Andrea Uva; Virginia Messia; Rebecca Nicolai; Manuela Pardeo; Fabrizio De Benedetti; Claudia Bracaglia
Journal:  Pediatr Rheumatol Online J       Date:  2021-09-16       Impact factor: 3.054

7.  Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register.

Authors:  Eoghan M McCarthy; Emily Sutton; Stephanie Nesbit; James White; Ben Parker; David Jayne; Bridget Griffiths; David A Isenberg; Anisur Rahman; Caroline Gordon; David P D'Cruz; Benjamin Rhodes; Peter Lanyon; Edward M Vital; Chee-Seng Yee; Christopher J Edwards; Lee-Suan Teh; Mohammed Akil; Neil J McHugh; Asad Zoma; Ian N Bruce
Journal:  Rheumatology (Oxford)       Date:  2018-03-01       Impact factor: 7.580

Review 8.  Novel Pharmacotherapies for Recurrent Pericarditis: Current Options in 2020.

Authors:  Enrico Tombetti; Alice Mulè; Silvia Tamanini; Luca Matteucci; Enrica Negro; Antonio Brucato; Carla Carnovale
Journal:  Curr Cardiol Rep       Date:  2020-06-19       Impact factor: 2.931

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.